Choose a country to view content specific to your location

Template is called...

Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready LAMP Mix

CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays. The Lyo-Ready DNA LAMP Mix is formulated for […]

Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay

CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Company’s new Curian® Campy assay. This assay is one of many assays […]

Meridian Launches its New Air-Dryable Mix for Crude Blood Samples

CINCINNATI, March 08, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Blood Mix, which is specifically designed for the manufacturing of room-temperature stable molecular diagnostic assays direct from whole blood, […]

Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal

CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. In […]

Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission

CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. Following the submission […]

Meridian Bioscience Provides an Update on the Revogene® SARS-CoV-2 EUA Submission

CINCINNATI, Feb. 16, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. In its ongoing discussion […]

Meridian Bioscience Reports Record Setting First Quarter Fiscal 2021 Operating Results and Raises Full Year Fiscal 2021 Guidance

CINCINNATI, Feb. 05, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020. First Quarter 2021 Highlights (Comparison to First Quarter Fiscal 2020): Consolidated net revenues of $92.9 million, up 96% year-over-year Life Science segment delivered net revenues of $62.6 million, up 396% year-over-year […]

Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown

CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company’s SARS-CoV-2 molecular diagnostic test on its Revogene® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration […]